retatrutide type 2 diabetes phase 2 results 2024 2025 Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, 3 retatrutide phase 2 trial type

High prevalence of malnutrition and micronutrient deficiencies in patients with inflammatory bowel disease early in disease course

Here's the part that trips people up: compounded semaglutide and compounded tirzepatide are not FDA-approved finished drug products

Participants over 55 responded nearly as well as younger cohorts, suggesting the mechanism works effectively regardless of age-related metabolic changes

Protocol adherence to the SPIRIT-PRO guidelines was assessed by a single reviewer using manifest content analysis

Education covers device type, storage, mixing when applicable, and safe needle disposal so home use is consistent

Kuzio, Dryburgh, Malloy, Brown